The two groups will combine efforts to genetically track threats ranging from mosquito borne pathogens to pandemic flu.
Neisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world, and it has become a superbug. It has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. Hear from clinicians advocating for their patients, a global leader, and a leading expert in drug development on actions needed to combat resistant gonorrhea.
Methicillin-resistant S. aureus (MRSA) is found in the community and in healthcare systems. According to the WHO, hospitalized patients with MRSA infections are 64% more likely to die than people with drug-sensitive infections. It can be difficult to treat. In this episode, hear from a patient who battled an infection for years, a infectious disease clinician who shares his daily challenges, and a researcher who using an unique approach to find the next antibiotic.
In this episode, we will explore the ways that antimicrobial resistance impacts treatment for some of the most vulnerable patients, such as those undergoing cancer treatment or receiving bone marrow transplants. A recent survey of oncologists showed that 95% of them worry about the impact of superbugs on the future of cancer treatments, and one in five patients receiving chemotherapy will have a bacterial infection. In this episode, you will hear directly from a patient who had a bacterial infection while fighting cancer, from front-line clinicians, and from a researcher driving policy at a national level.
HHS is expanding access through stockpiles that had been reserved for use in a future flu pandemic.
